Ferrous sulphate interacts with captopril

British Journal of Clinical Pharmacology

Volumn 46, Issue 4, 1998, Pages 377-381

  Schaefer, J P ^a   Tam, Y ^b   Hasinoff, B B ^c   Tawfik, S ^c   Peng, Y ^c   Reimche, L ^a   Campbell, N R C ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Captopril; Complex formation; Drug interaction; Heart failure; Hypertension; Iron

Indexed keywords

CAPTOPRIL; FERROUS SULFATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CONJUGATION; FEMALE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031686653     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.t01-1-00794.x     Document Type: Article

References (35)

1. Harju E. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet 1989; 17: 69-89.
2. Campbell NR, Hasinoff BB. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol 1991; 31: 251-255.
3. Neuvonen PJ, Gothoni G, Hackman K, Bjorksten K. Interference of iron with the absorption of tetracyclines in man. Br Med 1970; 4: 532-534.
4. Polk RE, Healy DP, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitaimns with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989; 33: 1841-1844.
5. Kara M, Hasinoff BB, McKay DW, Campbell NR. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 1991; 31: 257-261.
6. Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. Br J Clin Pharmacol 1992; 33: 115-116.
7. Campbell NR, Rankine D, Goodridge AE, Hasinoff BB, Kara M. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. Br J Clin Pharmacol 1990; 30: 599-605.
8. Campbell NR, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: Chelation as a possible mechanism. Clin Pharmacol Ther 1989; 45: 220-225.
9. Campbell N, Paddock V, Sundaram R. Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate. Clin Pharmacol Ther 1988; 43: 381-386.
10. Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med 1992; 117: 1010-1013.
11. Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate. Clin Pharmacol Ther 1983; 33: 465-470.
12. Osterman T, Juhakoski A, Lauren L, Sellman R. Effect of iron on the absorption and distribution of clodronate after oral administration in rats. Pharmacol Toxicol 1994; 74: 267-270.
13. Ueno K, Tanaka K, Tsujimura K, et al. Impairment of cefdinir absorption by iron ion. Clin Pharmacol Ther 1993; 54: 473-475.
14. Jay D, Cuellar A, Jay EG, Garcia C, Gleason R, Munoz E. Study of a fenton type reaction: Effect of captopril and chelating reagents. Arch Biochem Biophys 1992; 298: 740-746.
15. Lapenna D, De Gioia S, Mezzetti A, Ciofani G, Di Ilio C, Cuccurullo F. The prooxidant properties of captopril. Biochem Pharmacol 1995; 50: 27-32.
16. Hughes MA, Smith GL, Williams DR. The binding of metal ions by captopril (SQ 14225). Part I. Complex of zinc (II), Cadmium (II) and Lead (II). Inorg Chim 1985; 107: 247-252.
17. Misik V, Mak IT, Stafford RE, Weglicki WB. Reactions of captopril and epicaptopril with transition metal ions and hydroxyl radicals: An EPR spectroscopy study. Free Radic Biol Med 1993; 15: 611-619.
18. Jay D, Cuella A, Jay E. Superoxide dismutase activity of the captopril-iron complex. Mol Cell Biochem 1995; 146: 45-47.
19. Simonsen LL. What are pharmacists dispensing most often? Top 200 drugs of 1992. Pharm Times 1993; 29-39.
20. May FE, Stewart RB, Hale WE, Marks RG. Prescribed and nonprescribed drug use in an ambulatory elderly population. South Med J 1982; 75: 522-528.
21. Abbott D, Campbell N, Carruthers-Czyzewski P, et al. Guidelines for measurement of blood pressure, follow-up, and lifestyle counselling. Can J Public Health 1994; 2: 29s-43s.
22. Pereira CM, Tam YK, Collins-Nakai RL, Ng P. Simplified determination of captopril in plasma by high-performance liquid chromatography. J Chromatogr A 1988; 425: 208-213.
23. Ediss C, Tam YK. An interactive computer program for determining areas bounded by drug concentration curves using Lagrange interpolation. JPM 1995; 34: 165-168.
24. Hamed MY, Silver J, Wilson MT. Studies of the reactions of ferric iron with glutathione and some related thiols. Inorg Chim 1983; 78: 1-11.
25. Cheng KL, Ueno K, Imamura T. CRC Handbook of organic-analytical reagents. 1982; [Abstract].
26. Tanaka K, Kolthoff M, Stricks W. Iron-cysteinate complexes. J Am Chem Soc 1955; 77: 1996-2006.
27. Burnier M, Biollaz J. Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy. Clin Pharmacokinet 1992; 22: 375-384.
28. Duchin KL, McKinstry DN, Cohen AI, Migdalof BH. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmacokinet 1988; 14: 241-259.
29. Drummer OH, Jarrott B. Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat. Biochem Pharmacol 1984; 33: 3567-3571.
30. Drummer OH, Kourtis S, Jarrott B. Inhibition of angiotensin converting enzyme by metabolites of captopnl. Clin Exp Pharmacol Physiol. 1985; Suppl: 12-13.
31. Muller HH, Overtack A, Heck I, Kolloch R, Sumpe KO. The influence of food intake on pharmacodynamics and plasma concentration of captopril. J Hypertension 1985; S135-6.
32. Singhvi SM, McKinstry DN, Shaw JM, Willard DA, Migdalof BH. Effect of food on the bioavailability of captopril in healthy subjects. J Clin Pharmacol 1982; 22: 135-140.
33. Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol 1984; 22: 626-629.
34. Salvetti A, Pedrinelli R, Magagna A, et al. Influence of food on acute and chronic effects of captopril in essential hypertensive patients. J Cardiovasc Pharmacol 1985; 7(Suppl 1): S25-S29.
35. Ohman KP, Kagedal B, Larsson R, Karlberg BE. Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. J Cardiovasc Pharmacol 1985; 7(Suppl 1): S20-S24.